The company's lead product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD), which showed promising results in a Phase 2b clinical trial. AD04 is currently being investigated in the Company's ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. The company is also developing adenosine analogs for the treatment of pain and other disorders, and AD04 is believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity.